C Costagliola, L Romano, G Scibelli, A de Vincentiis, P Sorice, A Di Benedetto
doi:10.2337/db09-9028 3
This substantial participant database provides meaningful safety evidence across varied dosing regimens, administration routes (oral and injectable), and treatment durations, making it one of the more extensively studied peptide fragments in human clinical trials
Description Reviewed by Dr
Practical requirements include alternative text for all images, keyboard navigability without a mouse, sufficient colour contrast, captions for video content, and accessible online booking systems
A small and non-significant pooled SMD of 0.07 was reported for the effect of weight loss on total GLP-1 concentration changes (95% CI: 0.20 to 0.06